Document Detail

The use of luteinising hormone releasing hormone and its analogues for induction of ovulation and ovarian stimulation for in-vitro fertilisation.
MedLine Citation:
PMID:  2221814     Owner:  NLM     Status:  MEDLINE    
The use of subcutaneous pulsatile luteinising hormone releasing hormone (LHRH) for induction of ovulation in patients with hypogonadotrophic hypogonadism is efficacious and safer compared to human menopausal gonadotrophin (hMG) because of the lower risk of ovarian hyperstimulation and multiple pregnancy. In clomiphene citrate (CC) nonresponsive cases of polycystic ovarian disease (PCOD), the major advantage of pulsatile LHRH is that when ovulation occurs, it is usually uni-follicular. In cases of PCOD, we have found that if pulsatile LHRH alone fails to induce ovulation, addition of clomiphene citrate or a small dose of follicle stimulating hormone (FSH) will augment its action and allow, in the majority of cases, the threshold of stimulation to be reached that would be sufficient to induce ovulation but not produce clinical hyperstimulation or multiple pregnancy. LHRH analogues to desensitise the pituitary prior to ovarian stimulation with hMG have been recently used in in-vitro fertilisation (IVF). We have compared the use of the LHRH analogue, buserelin (Hoechst, UK) + hMG with clomiphene + hMG for ovarian stimulation in IVF in a number of prospective studies. In this review, the role of pituitary desensitisation in IVF is discussed in the light of our results. We have found that although the mean number of oocytes, the implantation rate and pregnancy rate per embryo transfer are higher in patients who receive buserelin + hMG, the differences are not statistically significant. The length of time taken to achieve pituitary desensitisation is increased in patients who have PCOD or who form ovarian cysts in response to the administration of buserelin.(ABSTRACT TRUNCATED AT 250 WORDS)
S L Tan; C Kingsland; N White; B A Mason; S Campbell
Related Documents :
7064834 - Atrioventricular alternating wenckebach periodicity: conduction patterns in multilevel ...
6354104 - Ovulation and pregnancy after pulsatile administration of gonadotropin releasing hormone.
16580374 - Effect of coasting on cycle outcome during in vitro fertilization/intracytoplasmic sper...
2567714 - Daily or alternate-day fsh therapy in patients with polycystic ovarian disease resistan...
17679084 - Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregna...
16595714 - Ectopic pregnancy in animals and humans.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of the Academy of Medicine, Singapore     Volume:  19     ISSN:  0304-4602     ISO Abbreviation:  Ann. Acad. Med. Singap.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-11-15     Completed Date:  1990-11-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7503289     Medline TA:  Ann Acad Med Singapore     Country:  SINGAPORE    
Other Details:
Languages:  eng     Pagination:  530-5     Citation Subset:  IM    
Department of Obstetrics and Gynaecology, King's College School of Medicine and Dentistry, Denmark Hill, London, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Fertilization in Vitro*
Gonadotropin-Releasing Hormone / analogs & derivatives,  pharmacology*
Hypogonadism / therapy
Ovulation Induction*
Pulsatile Flow
Risk Factors
Reg. No./Substance:
33515-09-2/Gonadotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The gonadotrophin surge in humans: its mechanism and role in ovulatory function--a review.
Next Document:  Persistent hypomagnesaemia following parathyroid surgery, hypermagnesuria as a possible cause.